Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AtriCure (ATRC) EBITDA (2016 - 2025)

AtriCure (ATRC) has disclosed EBITDA for 16 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA rose 110.63% to $1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$9.8 million, a 77.99% increase, with the full-year FY2025 number at -$9.8 million, up 77.99% from a year prior.
  • EBITDA was $1.7 million for Q4 2025 at AtriCure, up from -$443000.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $97.0 million in Q3 2021 to a low of -$17.7 million in Q1 2022.
  • A 5-year average of -$4.1 million and a median of -$8.2 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: soared 2122.14% in 2021, then plummeted 189.4% in 2023.
  • AtriCure's EBITDA stood at -$14.5 million in 2021, then skyrocketed by 79.48% to -$3.0 million in 2022, then tumbled by 189.4% to -$8.6 million in 2023, then plummeted by 91.39% to -$16.5 million in 2024, then skyrocketed by 110.63% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for ATRC's EBITDA are $1.7 million (Q4 2025), -$443000.0 (Q3 2025), and -$5.2 million (Q2 2025).